Кардиобезопасность триптанов в лечении приступов мигрени
https://doi.org/10.21518/2079-701X-2014-5-16-21
Аннотация
В статье освещаются вопросы безопасности применения триптанов в лечении мигрени и их влияние на риск кардиоваскулярных осложнений. Приведены результаты крупного проспективного популяционного исследования, которые продемонстрировали, что использование триптанов у больных мигренью не сопровождается увеличением риска значимых сердечно-сосудистых событий.
Список литературы
1. Куцемелов И.Б., Табеева Г.Р. Эпидемиология первичной головной боли. Боль, 2004, 4(5): 25-31.
2. Табеева ГР. Кардиобезопасность новейших триптанов. Боль, 2006, 4: 39-47.
3. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Yakhno N, Steiner TJ. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia, 2012, 32(5): 373-381.
4. Buring JE., Heberg P., Romero J et al. Migraine and subsequent risk stroke in Phisicians' Health Study. Arch Neurol., 1995, 52: 129-34.
5. Cortijo J, marti-Cabrera, Bernabeu E et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol, 1997, 122: 1455-63.
6. Diener HC, Jansen JP, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (cafergot) in the acute treatment of migraine: a multicenter, randomized, double-blind, placebo-controlled comparison. Eur Neurol., 2002, 47: 99-107.
7. Ferrari VD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-ht1B1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 2001, 358: 1668-75.
8. Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache, 2000, 40: 521-527.
9. Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology, 2000, 54: 1560-3.
10. Goldstein JA, Massey KD, Kirbi S et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia, 2004, 4: 515-521.
11. Lanteri-Minet M, Massiou H, Romatet S, Barba A, Lucas C, Allaf B. An Instrument to Assess Patient Perceptions of Satisfaction With Acute Migraine Treatment (EXPERT Study). Headache, 2011, 51: 590-601.
12. Lanteri-Minet M.What do patients want from their acute migraine therapy? EurNeurol., 2005, 53 (Suppl. 1): 3-9.
13. Lewis PJ, Barrington SF, Marslsen PK et al. A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13 NH3 positron emission tomography. Neurology, 1997, 48: 1542-50.
14. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 2001, 41 (7): 646-57.
15. Maassen VanDenBrink A, van den Broek RW, de Vries P, Bogers AJ, Avezaat CJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology, 2000, 55: 1524-30.
16. MacCregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey Headache, 2003, 43: 19-26.
17. MacLean MR, Clayton RA, Templeton AG et al. Evidence for 5-HT1-like receptor - mediated vasoconstriction in human pulmonary artery Br J Pharmacol, 1996, 119: 277-82.
18. Mathew NT, Hetiarachchi J, Alderman J. Tolerability and safety of eletriptan in treatment of migraine: a comprehensive review Headache, 2003, 43: 962-74.
19. Mathew NT, Schonen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg vs sumatriptan 100 mg. Headache, 2003, 43: 214-222.
20. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in large-scale epidemiological study of the United States. Arch Neurol, 1997, 54: 362-8.
21. Muir DF, MacCanu GP, Swan L et al. Haemodynamic and coronary effects of intravenous eletriptan, a 5-HT1B1D receptor agonist. Clin Pharmacol Ther, 1999, 66: 85-90.
22. Pascual J, Munoz R, Leira R. An open-label preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. Cephalalgia, 2001, 21: 680-4.
23. Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary. Nat Health Stat Report, 2008, 7: 1-38.
24. Rasmussen BK, Jensen R, Schroll M. Epidemiology of headache in a general population - prevalence study. J Clin Epidemiol, 1991, 44: 1147-1157.
25. Sacco S, Ripa P, Grassi D, Pistoia F, Ornello R, Carolei A, Kurth T. Peripheral vascular disfunction in migraine: a review. The Journal of Headache and Pain, 2013, 14: 80.
26. Sandrini G, Farklila M, Burgess G, Foster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled multiple migraine attack study Neurology, 2000, 59: 1210-7.
27. Silberstein SD. Practice parameter: evidence-based quidelines for migraine headache (an evidence-based review) - report of the quality standarts subcommittee of the American Academy of Neurology. Neurology, 2000, 55: 754-62.
28. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache:A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007, 27: 193-210.
29. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs, 2000, 60: 1259-1287.
30. Van den Broek RW, Maassen VanDenBrink A, De Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol, 2000, 407: 165-73.
31. Van den Broek RW, Maassen VanDenBrink A, Mulder PG, Bogers AJ, Avezaat CJ, John GW, Saxena PR. Comparison of contractile responses to donitrip-tan and sumatriptan in the human middle meningeal and coronary arteries. Eur J Pharmacol, 2002, 443: 125-32.
32. Velentgas P, Cole A, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache, 2004, 44: 642-51.
33. Welch KM, Mathew NT, Stone P et al. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia, 2000, 20: 687-95.
Рецензия
Для цитирования:
Табеева Г.Р. Кардиобезопасность триптанов в лечении приступов мигрени. Медицинский Совет. 2014;(5):16-21. https://doi.org/10.21518/2079-701X-2014-5-16-21
For citation:
Tabeyeva G.R. Cardiovascular safety of triptans in the acute treatment of migraine. Meditsinskiy sovet = Medical Council. 2014;(5):16-21. (In Russ.) https://doi.org/10.21518/2079-701X-2014-5-16-21
Просмотров: 309
Послать статью по эл. почте 